RE: Cure for cancer - deal with Nasdaq9 Jan 2025 12:48
Mr Eccleston at owns a little over 6% of the company as of today.
ValiRx plc has announced a change in its major shareholdings, with Mark Eccleston now holding a 6.08% voting rights position, including shares acquired through OncoLytika Ltd and Annette Williams. This adjustment in shareholding is part of a recent subscription, with Eccleston and OncoLytika Ltd subscribing to additional ordinary shares, marking a strategic movement in the company’s shareholder distribution. This shift could potentially impact ValiRx’s governance and future financing strategies.